Exclusive Summary

• Perfect Market Timing: The core patent expired in 2023, opening up the global generic market and offering a prime opportunity for early entrants to capture market share.
• Clear & Rigid Market Demand: Over 400,000 new cases of multidrug-resistant TB occur annually, concentrated in high-burden countries, ensuring a large and stable market.
• Core & Solid Clinical Status: Listed as a WHO Essential Medicine and recommended as a cornerstone therapy in all-oral regimens for drug-resistant TB, making its clinical value indispensable.
• Significant Cost Advantage to Expand Access: Offers a substantial price reduction compared to the originator drug, enabling governments and global organizations to expand treatment coverage within limited budgets.